| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J M Derocq, M Ségui, J Marchand, G Le Fur, P Casella. Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS letters. vol 369. issue 2-3. 1995-09-22. PMID:7544292. |
in addition, the absence of antagonistic effect of sr141716a, a specific cb1 receptor antagonist, together with the demonstration that human b-cells displayed large amount of cb2 receptor mrnas, led us to assume that the growth enhancing activity observed on b-cells at very low concentrations of cannabinoids could be mediated through the cb2 receptor. |
1995-09-22 |
2023-08-12 |
human |
| R Mechoulam, S Ben-Shabat, L Hanus, M Ligumsky, N E Kaminski, A R Schatz, A Gopher, S Almog, B R Martin, D R Compto. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical pharmacology. vol 50. issue 1. 1995-08-10. PMID:7605349. |
2-ara-gl bound to membranes from cells transiently transfected with expression plasmids carrying dna of either cb1 or cb2--the two cannabinoid receptors identified thus far--with ki values of 472 +/- 55 and 1400 +/- 172 nm, respectively. |
1995-08-10 |
2023-08-12 |
mouse |
| A C Howlet. Pharmacology of cannabinoid receptors. Annual review of pharmacology and toxicology. vol 35. 1995-08-01. PMID:7598509. |
two subtypes of cannabinoid receptors, cb1 and cb2, have been described to date, although future investigations may elucidate other receptors. |
1995-08-01 |
2023-08-12 |
Not clear |
| L Facci, R Dal Toso, S Romanello, A Buriani, S D Skaper, A Leo. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proceedings of the National Academy of Sciences of the United States of America. vol 92. issue 8. 1995-05-25. PMID:7724569. |
the results suggest that (i) peripheral cannabinoid cb2 receptors control, upon agonist binding, mast cell activation and therefore inflammation; (ii) palmitoylethanolamide, unlike anandamide, behaves as an endogenous agonist for the cb2 receptor on mast cells; (iii) modulatory activities on mast cells exerted by the naturally occurring molecule strengthen a proposed autacoid local inflammation antagonism (alia) mechanism; and (iv) palmitoylethanolamide and its derivatives may provide antiinflammatory therapeutic strategies specifically targeted to mast cells ("aliamides"). |
1995-05-25 |
2023-08-12 |
Not clear |